Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 18/20 | 0.76 |
| ▸ | CHRNA4 | P43681 | 18/20 | 0.76 |
| ▸ | CHRNB4 | P30926 | 17/20 | 0.76 |
| ▸ | CHRNA3 | P32297 | 17/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL649878 | 1.00 | CHRNB2 (0.76) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL1526888 | 1.00 | CHRNB2 (0.76) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL651976 | 0.99 | CHRNB2 (0.74) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL652378 | 0.99 | CHRNB2 (0.74) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL652757 | 0.92 | CHRNB2 (0.80) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL27594104 | 0.92 | CHRNB2 (0.80) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL652756 | 0.92 | CHRNB2 (0.80) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL652719 | 0.90 | CHRNB2 (0.72) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL652720 | 0.90 | CHRNB2 (0.72) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL652718 | 0.90 | CHRNB2 (0.72) | CHRNB2CHRNA4CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024018395-A1 | METHODS AND INTERMEDIATES FOR PREPARING 2-[(4-{6-[(4-CYANO-2-FLUOROBENZYL)OXY]PYRIDIN-2-YL}PIPERIDIN-1-YL)METHYL]-1-[(2S)-OXETAN-2-YLMETHYL]-1H-BENZIMIDAZOLE-6-CARBOXYLIC ACID, 1,3-DIHYDROXY-2-(HYDROXYMETHYL)PROPAN-2-AMINE SALT | PFIZER INC. (US) | 2024-01-25 | — | — | WO | claimed |
| EP-3454898-B1 | DRUG COMBINATIONS FOR REDUCING CELL VIABILITY AND/OR CELL PROLIFERATION | EISAI R&D MAN CO LTD (JP) | 2021-11-10 | — | — | EP | claimed |
| EP-3255031-B1 | COMPOUND, AND SEPARATION METHOD, SYNTHESIS METHOD AND USE THEREOF | BEIJING PEKING UNIV WBL BIOTECH CO LTD (CN) | 2021-09-29 | — | — | EP | claimed |
| US-10099998-B2 | Compound, and separation method, synthesis method and use thereof | BEIJING PEKING UNIVERSITY WBL BIOTECH CO., LTD. (CN) | 2018-10-16 | — | — | US | claimed |
| US-20180022688-A1 | COMPOUND, AND SEPARATION METHOD, SYNTHESIS METHOD AND USE THEREOF | BEIJING PEKING UNIVERSITY WBL BIOTECH CO., LTD. (CN) | 2018-01-25 | — | — | US | claimed |
| EP-2579377-B1 | NONAQUEOUS ELECTROLYTE SOLUTION AND ELECTROCHEMICAL ELEMENT USING SAME | UBE INDUSTRIES (JP) | 2014-09-03 | — | — | EP | claimed |
| EP-2400033-B1 | Method for determining sensitivity of tumor cells to tyrosine kinase inhibitor and computer program product | SYSMEX CORP (JP) | 2013-02-20 | — | — | EP | claimed |
| EP-2111401-B1 | 4-{4-[({3-TERT-BUTYL-1-[3-(HYDROXYMETHYL) PHENYL]-1H-PYRAZOL-5-YL } CARBAMOYL)-AMINO]-3-FLUOROPHENOXY} -N-METHYLPYRIDINE-2-CARBOXAMIDE AS WELL AS PRODRUGS AND SALTS THEREOF FOR THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC (US) | 2011-02-16 | — | — | EP | claimed |
| US-6809105-B2 | (CIS)-6-(3-PYRIDINYL)-3,6-DIAZABICYCLO(3.2.0) HEPTANE FOR EXAMPLE; ALZHEIMER'S DISEASE, PARKINSON'S DISEASE, ATTENTION DEFICIT HYPERACTIVITY DISORDER, DEPRESSION, NICOTINIC WITHDRAWAL SYNDROME, TOURETTE'S SYNDROME, AND SCHIZOPHRENIA | ABBOTT LABORATORIES | 2004-10-26 | — | — | US | claimed |
| US-20040186107-A1 | Diazabicyclic central nervous system active agents | ABBVIE INC. | 2004-09-23 | — | — | US | claimed |
| EP-1284976-A2 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | Abbott Laboratories (US) | 2003-02-26 | — | — | EP | claimed |
| US-20020019388-A1 | Diazabicyclic central nervous system active agents | ABBVIE INC. | 2002-02-14 | — | — | US | claimed |
| WO-2001081347-A2 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | ABBOTT LABORATORIES (US) | 2001-11-01 | — | — | WO | claimed |
| US-20240199587-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2024-06-20 | — | — | US | disclosed |
| EP-4329826-A1 | DEUTERATED COMPOUNDS AND IMAGING AGENTS FOR IMAGING HUNTINGTIN PROTEIN | CHDI Foundation, Inc. (US) | 2024-03-06 | — | — | EP | disclosed |
| EP-4326714-A1 | HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-02-28 | — | — | EP | disclosed |
| WO-2001081347-A2 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | ABBOTT LABORATORIES (US) | 2001-11-01 | — | — | WO | disclosed |
| EP-1147112-A1 | DIAZABICYCLIC DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2001-10-24 | — | — | EP | disclosed |
| WO-2000044755-A1 | DIAZABICYCLIC DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2000-08-03 | — | — | WO | disclosed |
| US-4338453-A | Aminoalkyl-1,2,4-triazoles | THE UPJOHN COMPANY (US) | 1982-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199587-A1 | HETEROCYCLIC COMPOUNDS | CYP1B1, CYP1A1, CYP4B1 | CHRNB2 2449/4885CHRNA4 2283/4885CHRNB4 1971/4885 |
| US-20020019388-A1 | Diazabicyclic central nervous system active agents | GAP43, GABRE, CHRNA6 | CHRNB2 11/4885CHRNA4 8/4885CHRNB4 15/4885 |
| US-20180022688-A1 | COMPOUND, AND SEPARATION METHOD, SYNTHESIS METHOD AND USE THEREOF | HMGCR, COASY, DHCR7 | CHRNB2 4516/4885CHRNA4 4632/4885CHRNB4 4525/4885 |
| US-20040186107-A1 | Diazabicyclic central nervous system active agents | GAP43, GABRE, CHRNA6 | CHRNB2 11/4885CHRNA4 8/4885CHRNB4 15/4885 |
| US-10099998-B2 | Compound, and separation method, synthesis method and use thereof | HMGCR, COASY, DHCR7 | CHRNB2 4516/4885CHRNA4 4632/4885CHRNB4 4525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.